A
Andrey Akopov
Publications - 2
Citations - 524
Andrey Akopov is an academic researcher. The author has contributed to research in topics: Atezolizumab & Lung cancer. The author has an hindex of 2, co-authored 2 publications receiving 23 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.
Enriqueta Felip,Nasser K. Altorki,Caicun Zhou,Tibor Csőszi,Ihor Vynnychenko,Oleksandr Goloborodko,Alexander Luft,Andrey Akopov,Alex Martinez-Marti,Hirotsugu Kenmotsu,Yuh-Min Chen,Antonio Chella,Shunichi Sugawara,David Voong,Fan Wu,Jing Yi,Yu Deng,Mark McCleland,Elizabeth Bennett,Barbara J. Gitlitz,Heather A. Wakelee,IMpower Investigators +21 more
TL;DR: The IMpower010 trial as mentioned in this paper evaluated adjuvant atezolizumab versus best supportive care (observation and regular scans for disease recurrence) in patients with early-stage non-small-cell lung cancer.
Journal ArticleDOI
IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
Heather A. Wakelee,Nasser K. Altorki,Caicun Zhou,Tibor Csőszi,Ihor Vynnychenko,Oleksandr Goloborodko,Alexander Luft,Andrey Akopov,Alex Martinez-Marti,Hirotsugu Kenmotsu,Yuh Min Chen,Antonio Chella,Shunichi Sugawara,Barbara J. Gitlitz,Elizabeth Bennett,Fan Wu,Jing Yi,Yu Deng,Mark McCleland,Enriqueta Felip +19 more
TL;DR: Adjuvant platinum-based chemotherapy provides only a modest 5-year survival benefit in fully resected, high-risk early-stage NSCLC and the primary disease-free survival benefit is reported.